Via Celoria 11 - 20133 Milan - ITALY
Direttore UOC Neurologia 5 - Neuropatologia
Personal presentation and training
Neurologist with extensive clinical and neuropathological experience in the field of neurodegenerative diseases. The main areas of research are Alzheimer's disease and prion diseases,with the use of a variety of approaches including classical neuropathology, immunohistochemistry, molecular biology. Degree in Medicine and Surgery, 1984, University of Turin. He passed the ECFMG (1984) and FMGEMS (1985) exams for the recognition of the degree in the United States. Specialization in Neurology, 1988 University of Turin (prof. D. Schiffer).
From 1986 to 1991: scholarships and research contracts at the Besta Neurological Institute. Roussel Italia Prize for neurological research (1990). Neurologist Medical Director (since 1991) and then Acting Director (since 2016), UOC Neurology 5 - Neuropathology, Besta Neurological Institute.
Care and outpatient activities
Inpatient and outpatient sector dedicated to the diagnosis and treatment of degenerative dementias, prion diseases and other conditions characterized by cognitive impairment.
It is possible to be received both for private visits and for hospitalizations by calling or writing to the secretariat of NEUROPATHOLOGY 5:
phone. +39 02.2394.2260 (from 09.00 to 12.30)
fax +39 02.2394.2101
Sectors of activity: Neurodegenerative and genetic dementias (Dr. Zanusso) Prion disease (sporadic, acquired and genetic forms of Creutzfeldt- Jakob and Gerstmann Straussler Scheinker- Dr. Zanusso). Other rapidly evolving dementias. The Neuropathology Section is located on the 7th floor of lot I of the "G.B. Rossi" Polyclinic Borgo Roma, Piazzale L. Scuro, 10 - 37134 Verona- Italy.
PROF. GIANLUIGI ZANUSSO
Telefono: +39 0458124285
He is a neurologist who trained in research studying prion diseases. However, his research activity covers all neurodegenerative diseases due to protein misfolding. In particular, Alzheimer's disease, sporadic prion diseases (CJD) and genetic (Gerstmann Straussler Scheinker), alpha-synucleinopathies and taupathies. The main objective is to be able to formulate a molecular diagnosis in vivo using in vitro oligomer replication techniques (RT-QuIC) as already achieved in Creutzfeldt-Jakob disease. The techniques we use in the laboratory are biochemical and in particular the in vitro replication techniques. The nasal diagnostic test, called RT-QuIC, was discovered by him after about 20 years of study in collaboration with the staff of Prof. Byron Caughey, Ph.D. in the state of Montana (United States).
Now let's listen to Prof. Zanusso in the video taken from YouTube below: he will explain what he has been doing in all these years together with his staff and the staff of Prof. Byron Caughey in the state of Montana, U.S. (in English).
It is the most powerful and effective world center for follow up and therapy for prion diseases. Managed by Prof. John Collinge and Dr. Simon Mead, they are testing with good results a monoclonal antibody, called PRN100 which in cases where CJD disease (and in the future also GSS) was in its infancy, the disease stopped. It is the biggest bet in the world in the field of therapies, although bureaucracy and science take time.
Prof John Collinge
Professor of Neurology
Head of Department
MRC Prion Unit at UCL
UCL Institute of Prion Diseases
Dott. Simon Mead
UCL INSTITUTE OF NEUROLOGY